Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal
À propos du CIUSSS
Accueil Plan du site Courrier Portail Québec
Size of text


December 09, 2013 Publications

How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy?

Two pharmacists from UdeM and the Institut universitaire en santé mentale de Montréal give us some answers.

The clinical context of the administration and dosage of antipsychotics may influence their efficacy, reported Philippe Vincent and Édouard Kouassi, from the Institut universitaire en santé mentale de Montréal and Université de Montréal. The efficacy of most antipsychotics depends on their pharmacokinetics, or their ability to get into the bloodstream after being absorbed. Vincent and Kouassi are responding in The Lancet1 to Stefan Leucht, who conducted a meta-analysis of over 200 articles on the efficacy and side effects of 15 antipsychotics.2 According to the data Leucht collected, five of the most recent second-generation antipsychotics (ziprasidone, aripiprazole, asenapine, iloperidone and lurasidone) were among the drugs with the lowest efficacy, despite having similar pharmacological properties compared to first-generation or to other second-generation antipsychotics. Leucht published his finding in The Lancet in September 2013; his article did not give any explanations for this surprising result.

Some antipsychotics require strict adherence on the part of patients. According to Vincent and Kouassi, specific conditions are required for some medications to be effectively absorbed. “For example, ziprasidone needs to be taken twice a day with a meal of 500 calories, whereas asenapine must absolutely melt under the tongue, and the patient must abstain from swallowing it, drinking, eating or smoking for 10 minutes afterward,” Vincent said “This is a major challenge since more than one half of people with psychotic disorders do not take their medication as prescribed.”

Vincent and Kouassi also state that the titration of these antipsychotics is a challenge in clinical practice, as it is difficult to obtain the optimal therapeutic dosage on the first try. Doctors therefore have to use an empirical approach. “The major side effects show up well before the optimum therapeutic dose is determined, which can discourage patients from continuing their treatment,” Kouassi said. “Doctors have to keep trying, as the pharmacokinetics of antipsychotic compounds differ for each patient. By adjusting the dose of a medication based on the degree of blood absorption, distribution, metabolism and elimination in a patient, doctors can personalize treatment, which becomes that much more effective.  We maintain that all antipsychotics, with the exception of clozapine, can achieve the same efficacy if they reach comparable blood levels.”

If the studies reported by Leucht had compared medications in terms of their blood concentrations, we would have more accurate conclusions about the efficacy of the medication. “This confirms that the future of psychiatric medicine will involve personalizing patient care,” Vincent said.

  1. Vincent P, Kouassi E. Efficacy of antipsychotic drugs for schizophrenia (Letter to Editors). The Lancet – 7 December 2013 (Vol. 382, Issue 9908, Pages 1873-1874 DOI: 10.1016/S0140-6736(13)62615-X
  2. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62.




About the researchers

Édouard Kouassi, who has a PhD in Pharmacology, is a researcher at the Institut universitaire en santé mentale de Montréal and an associate professor and researcher in the Faculty of Medicine at Université de Montréal. His work aims to identify blood biomarkers in psychiatric illnesses, such as schizophrenia and major depression. He also studies the mechanisms of action of serotonin on the survival of red blood cells and its role in transfusion medicine as well as the role of serotonin receptors in immune cells.

Philippe Vincent is a clinical pharmacist who specializes in psychiatry at the Institut universitaire en santé mentale de Montréal and an assistant clinical professor at the Faculty of Pharmacy at Université de Montréal. His research looks at specialized pharmaceutical care in psychiatry and the treatment compliance of people who suffer from schizophrenia.


About the Institut universitaire en santé mentale de Montréal

The Institut universitaire en santé mentale de Montréal (IUSMM) provides specialized and ultraspecialized services in mental health. A leader in its field, it develops knowledge through research, teaching and assessment. The IUSMM is a member of the large network of excellence in health of Université de Montréal.

About the Research Centre of the IUSMM

At the forefront of knowledge, the Research Centre of the IUSMM is one of the largest venues for clinical research in mental health in French Canada. Through its partnership with the research department at Hôpital Rivière-des-Prairies and the Research Centre of the Institut Philippe-Pinel de Montréal, it has the largest number of mental health researchers from the faculties of medicine, arts and sciences, and nursing from Université de Montréal and other universities.



Catherine Dion
Communications Department – Institut universitaire en santé mentale de Montréal
Phone: 514-251-4000, extension 2986 - Cell: 514-235-4036

Back to News Back to Home